KNOWLEDGE, ATTITUDE AND PRACTICE OF YEMENI PHYSICIANS TOWARD PHARMACOVIGILANCE: A MIXED METHOD STUDY
Objective: The objective of the current study was to investigate the physicianâ€™s knowledge, attitude and practice towards pharmacovigilance.
Methods: A mixed qualitative and quantitative method was conducted in this study using a face to face questionnaire among the physicians in the capital Sana'a, Yemen.
Results: Of the 105 respondents (79 %) were male. Participants age mean was 35.55Â±4.45 y. Majority of physicians (73.3 %) had a moderate knowledge towards pharmacovigilance; (15.2 %) had a good knowledge and (11.4 %) had a poor knowledge. 35 (33.3 %) physicians were seen adverse drug reactions (ADRs) happened to their patients. Allergy was the most common ADRs. However, no ADR was reported. 66.7 % of physicians had a positive attitude towards pharmacovigilance. The most barriers reported by physicians were: lack of motivation and lack of knowledge about reporting system. Reported factors to encourage ADRs reporting were: attend courses or workshops; educational materials and simplification of reporting procedures.
Conclusion: Majority of physicians in Sanaâ€™a, Yemen had moderate knowledge and postitive attitude towards pharmacovigilance. Educational and training programmes are the cornerstone of improving ADRs reporting in Yemen.Â
2. World Health Organization. The safety of medicines in public health programmes: pharmacovigilance, an essential tool; 2006. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigilance_B.pdf. [Last accessed on 10 Apr 2018]
3. Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug safety 2006;29:385-96.
4. HÃ¤rmark L, Van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008;64:743-52.
5. World Health Organization. International drug monitoring: the role of national centres, report of a WHO meeting; 1971. Available from: http://apps.who.int/iris/handle/10665/40968. [Last accessed on 10 Apr 2018]
6. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. Br Med J 1998;316:1295â€“8.
7. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993;27:832â€“40.
8. Pirmohamed M, James S, Meakin S. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 2004;329:15â€“9.
9. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
10. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6.
11. Yemeni Pharmacovigilance Center (YPVC); 2014. Available from: http://www.ypvc-sbd.com. [Last accessed on 01 May 2014]
12. Al-Worafi YM. Comment on: pharmacovigilance in the middle East. Drug Safety 2014;37:651.
13. Scott HD, Thacher-Renshaw A, Rosenbaum SE, Waters WJ, Green M, Andrews LG, et al. Physician reporting of adverse drug reactions. JAMA 1990;263:1785-8.
14. Cosentino M, Leoni O, Banfi F, Lecchini S, Frigo G. Attitudes to adverse drug reaction reporting by medical practitioners in a Northern Italian district. Pharmacol Res 1997;35:85-8.
15. Ministry of Public Health and Population. Annual statistical health report; 2014. Available from: http://www.mophp-ye.org/arabic/ docs/Report2014.pdf. [Last accessed on 10 Apr 2018]
16. Pharmacovigilance guideline. World Health Organization. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/S.AfricaDraftGuidelines.pdf. [Last accessed on 10 Apr 2018]
17. Al-Worafi YM, Kassab YW, Alseragi WM, Almutairi MS, Ahmed A, Ming LC, et al. Pharmacovigilance and adverse drug reaction reporting: a perspective of community pharmacists and pharmacy technicians in sanaâ€™a, Yemen. Ther Clin Risk Management 2017;13:1175.
18. Van Grootheest AC, Mes K, De Jong-Van, Den Berg LTW. Attitudes of community pharmacists in the Netherlands towards adverse drug reaction reporting. Int J Pharm Practice 2002;10:267-72.
19. Abdel-Latif MM, Abdel-Wahab BA. Knowledge and awareness of adverse drug reactions and pharmacovigilance practices among healthcare professionals in Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia. Saudi Pharm J 2015;23:154-61.
20. Iffat W, Shakeel S, Rahim N, Anjum F, Nesar S, Ghayas S. Pakistani physicians knowledge and attitude towards reporting adverse drug reactions. Afr J Pharm Pharmacol 2014;8:379-85.
21. Adedeji WA, Ibraheem WA, Fehintola FA. Attitude and practice of doctors toward adverse drug reactions (ADRs) reporting in a Nigerian tertiary health facility. Annals Ibadan Postgraduate Med 2013;11:77-80.
22. Lopez Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions. Drug Safety 2009;32:19-31.
23. Agarwal R, Daher AM, Ismail NM. Knowledge, practices and attitudes towards adverse drug reaction reporting by private practitioners from Klang Valley in Malaysia. Malaysian J Med Sci 2013;20:52.
24. AL-Worafi YM. Pharmacy practice in Yemen. In: Pharmacy Practice in Developing Countries: Achievements and Challenges; 2016. p. 267â€“87.
25. Raut AS, Pawar AT, Pankaj MA, Srivastava PR, Mishra AD. Clinical pattern and severity of cutaneous adverse drug reactions. Int J Pharm Pharm Sci 2013;5:612-6.